The stock of Pacific Biosciences of California Inc (NASDAQ:PACB) last traded at $1.48, down -1.33% from the previous session.
PACB stock price is now 27.10% away from the 50-day moving average and -4.97% away from the 200-day moving average. The market capitalization of the company currently stands at $444.13M.
, while ‘JP Morgan’ rates the stock as ‘Neutral’
In other news, Farmer Michele, insider sold 5,195 shares of the company’s stock on May 19 ’25. The stock was sold for $5,200 at an average price of $1.00. Upon completion of the transaction, the insider now directly owns 269,259 shares in the company, valued at $0.4 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 03 ’25, HENRY CHRISTIAN O sold 12,497 shares of the business’s stock. A total of $17,583 was realized by selling the stock at an average price of $1.41. This leaves the insider owning 2,225,357 shares of the company worth $3.29 million. A total of 11.97% of the company’s stock is owned by insiders.
During the past 12 months, Pacific Biosciences of California Inc has had a low of $0.85 and a high of $2.72. As of last week, the company has a debt-to-equity ratio of 7.63, a current ratio of 6.68, and a quick ratio of 5.87. The fifty day moving average price for PACB is $1.1642 and a two-hundred day moving average price translates $1.5575 for the stock.
The latest earnings results from Pacific Biosciences of California Inc (NASDAQ: PACB) was released for 2025-03-31. The net profit margin was -430.93% and return on equity was -177.29% for PACB. The company reported revenue of $37.15 million for the quarter, compared to $38.81 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -4.27 percent.
